Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Go back to Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy| Veramark Technologies, Inc. (NASDAQ: VERA) | Delayed: 35.29 -0.6 (1.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.89 | 52 Week High | $1.18 | |||
| Open | $35.80 | 52 Week Low | $0.36 | |||
| Day High | $36.00 | P/E | 588.17 | |||
| Day Low | $34.93 | EPS | $0.06 | |||
| Volume | 98,395 | |||||
